Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong.
Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):e98-e110. doi: 10.1111/j.1442-9071.2011.02684.x.
Myopic choroidal neovascularization (CNV) is a vision-threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle-aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized-controlled study in treatment of subfoveal myopic CNV. However, its long-term benefit is controversial. Recently, intravitreal injections of anti-vascular endothelial growth factors have shown promising results. In the absence of randomized-controlled trial comparing the efficacy of anti-vascular endothelial growth factors with photodynamic therapy and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic CNV. Furthermore, the influences of various doses and frequencies, as well as age and previous photodynamic therapy treatment on its effect are described.
近视性脉络膜新生血管（CNV）是病理性近视患者致盲的严重并发症，在全球范围内尤其在中青年人中多见。迄今为止，光动力疗法研究中的维替泊芬是唯一一项治疗中心性近视性脉络膜新生血管的随机对照研究。但是，其长期疗效存在争议。最近，玻璃体内注射抗血管内皮生长因子已显示出良好的效果。在缺乏比较抗血管内皮生长因子与光动力疗法和安慰剂疗效的随机对照试验的情况下，本文旨在综述中心性和旁中心性近视性脉络膜新生血管的功能和解剖学结果的现有研究。此外，还描述了不同剂量和频率以及年龄和既往光动力疗法治疗对其疗效的影响。
